Please sign in to follow a disease.
Primary cutaneous lymphoma
MONDO:0018898Cutaneous lymphoma is a heterogeneous entity with respect to its clinical and pathological features, evolutive profile, prognosis, molecular etiology and response to therapy. These specifications have been taken into account in recent classifications, which have placed particular importance on the prognostic implications of these different entities.
Also known as: cutaneous (skin) lymphoma, primary cutaneous lymphoma, primary skin lymphoma
3212 clinical trials for this condition and its sub-types, 6 tagged with Primary cutaneous lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Primary cutaneous lymphoma
-
Primary cutaneous T-cell non-Hodgkin lymphoma 83 trials · 125 incl. sub-types
5 sub-types
- Mycosis fungoides 82 trials
- Sezary syndrome 45 trials
- Primary cutaneous anaplastic large cell lymphoma 11 trials
- Mycosis fungoides variant 1 trial · 3 incl. sub-types Sub-types →
- Primary cutaneous gamma-delta t-cell lymphoma 3 trials
-
Primary cutaneous T-cell lymphoma 4 trials · 92 incl. sub-types
4 sub-types
-
Primary cutaneous B-cell lymphoma 5 trials · 7 incl. sub-types
1 sub-type
- Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types Sub-types →
Most studied deeper sub-types
-
New drug shows promise for controlling rare skin cancers
Disease control OngoingThis study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC